New full-body scanner may slash scan times for cancer patients
NCT ID NCT04478318
First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This study compares a new total-body PET/CT scanner (uEXPLORER) with a conventional PET/CT scanner in 180 adults with lung cancer, lymphoma, or melanoma. Each participant gets scanned on both machines to see if the new scanner can produce equally good images in a shorter time. The goal is to find the minimum scan duration needed for clear images, which could make future scans faster and more comfortable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that the new scanner provides equally good images in much less time, making scans faster and more comfortable for patients.
- What could go wrong
- This is an early comparison study, not a treatment trial. It only tests image quality, not whether the new scanner improves health outcomes. Results may not apply to other cancers or scanners.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLUORODEOXYGLUCOSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Could muscle loss predict blood cancer outcomes?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can new drug cocktails reawaken the immune system against melanoma?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?